Aug 06, 2021 8:30am EDT Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST
Aug 04, 2021 8:30am EDT Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
Jul 27, 2021 8:30am EDT Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
Jul 06, 2021 8:15am EDT Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
Jun 17, 2021 9:15am EDT PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
Jun 07, 2021 4:05pm EDT Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
May 20, 2021 4:05pm EDT Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
